Clinical Trials Browser

marizomib × Clear all

NCT03345095 2025-07-01

MIRAGE

Phase 3 Completed

749 enrolled 15 charts

Glioblastoma

NCT05050305 2024-07-16

Marizomib Central Nervous System (CNS)

Phase 2 Withdrawn

Multiple Myeloma

NCT04341311 2024-02-15

DIPG

Phase 1 Terminated

Diffuse Intrinsic Pontine Glioma, Neoplasms, Recurrence

NCT02330562 2022-06-08

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

Phase 1/2 Completed

121 enrolled 27 charts

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02903069 2021-04-19

Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Glioma

NCT04644107 2020-11-25

Expanded Access for Marizomib

No longer available

Other solid neoplasm

Solid Tumor

NCT00461045 2017-12-19

Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

Phase 2 Completed

15 enrolled 20 charts

Multiple Myeloma, Recurrence

NCT00629473 2017-11-22

Phase 1 Clinical Trial of NPI-0052 in Patients With Advanced Malignancies

Phase 1 Completed

DermatologicLymphoidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Lymphoma, T-Cell, Cutaneous, Lymphoma, B-Cell, Marginal Zone

NCT00667082 2017-11-22

NPI-0052 and Vorinostat in Patients With Non-small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma

Phase 1 Completed

DermatologicGastrointestinalLymphoidPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung, Lymphoma, Melanoma, Multiple Myeloma, Pancreatic Neoplasms

NCT02103335 2017-11-22

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Phase 1 Completed

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell